85426-79-5

Usage

Uses

Used in Pharmaceutical Development:
4-CHLORO-6-(METHYLTHIO)-1H-PYRAZOLO[3,4-D]PYRIMIDINE is used as a pharmaceutical intermediate for the development of new drugs. Its unique structure allows it to be a key component in the creation of novel therapeutic agents, potentially leading to advancements in medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 4-CHLORO-6-(METHYLTHIO)-1H-PYRAZOLO[3,4-D]PYRIMIDINE is utilized as a building block for synthesizing a variety of organic compounds. Its presence in these syntheses can contribute to the formation of complex molecules with specific properties, useful in various chemical and industrial applications.
Used in Research and Development:
4-CHLORO-6-(METHYLTHIO)-1H-PYRAZOLO[3,4-D]PYRIMIDINE is employed as a research compound in academic and industrial laboratories. Its unique structure and properties make it a valuable tool for studying chemical reactions and exploring new areas of chemistry, potentially leading to the discovery of new compounds and applications.

InChI:InChI=1/C6H5ClN4S/c1-12-6-9-4(7)3-2-8-11-5(3)10-6/h2H,1H3,(H,8,9,10,11)

Upstream product

• 5334-26-9 6-(methylthio)pyrazolo<3,4-d>pyrimidin-4(5H)-one 
• 24521-76-4 4-hydroxy-6-mercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 33097-11-9 4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxyaldehyde 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 
• 24521-76-4 6-thioxo-1,5,6,7-tetrahydropyrazolo<3,4-d>pyrimidin-4-one 
• 5334-26-9 4-hydroxy-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 5444-29-1 6-methylsulfanyl-1⁽²⁾H-pyrazolo[3,4-d]pyrimidin-4-ylamine 
• 55084-74-7 6-methylsulfanyl-1⁽²⁾H-pyrazolo[3,4-d]pyrimidine 
• 594865-24-4 (3-fluoro-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-03-9 (6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(4-nitro-benzyl)-amine 
• 594865-25-5 (3-methoxy-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-02-8 benzyl-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 594865-23-3 (3-bromo-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 5334-26-9 6-(methylthio)pyrazolo<3,4-d>pyrimidin-4(5H)-one 
• 5472-41-3 4-amino-1,7-dihydro-pyrazolo[3,4-d]pyrimidin-6-one 
• 1338789-21-1 4-chloro-6-(methylthio)-1-(2-phenylethyl)-1H-pyrazolo[3,4-d]-pyrimidine 
• 1583284-77-8 4-chloro-1-(2-methoxy-2-phenylethyl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine 
• 1470290-91-5 1-benzyl-4-chloro-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine 
• 1338789-23-3 N-(3-chlorophenyl)-6-(methylthio)-1-(2-phenylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1583284-80-3 N-cyclohexyl-6-(methylthio)-1-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS

New pyrimidine derivatives of formula (I), optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. New pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

Exploring the chemical space around the privileged pyrazolo[3,4-d] pyrimidine scaffold: Toward novel allosteric inhibitors of T315I-mutated Abl

A library of pyrazolo[3,4-d]pyrimidines, endowed with a high level of molecular diversity, has been developed applying a synthetic sequence that allowed C3, N1, C4, and C6 substitution. The enzymatic screening of this "privileged scaffold"-based compound collection, validated the use of a diversity-oriented approach in a field characteristically explored by target-oriented synthesis. In fact, several compounds showed high activity against the selected kinases (i.e., Src, Abl wt, and T315I mutated-form), furthermore and interestingly a new compound has emerged as an allosteric inhibitor of the T315I mutated-form of Abl, opening up new opportunities for the development of a novel class of noncompetitive inhibitors of Abl (T315I).

FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS

Fused pyrazoles effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same

Compounds of the formula Ia or Ib: wherein A, B, X, Y, Z, W, k, R1, R2, R3, R4 and R5 are those defined herein, and compositions comprising the same. The present invention also provides methods for pr

Heteroaryl-fused pyrazolo derivatives and methods for using the same

Compounds of the formula I: where A, B, X, Y, Z, k, R1, R2 and R3 are those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using t

Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors

A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines 15-19, 30-38 capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biological evaluation was carried out and structure-activity relationship was examined. In our series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds. The compounds 33a,b having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds. In general, the unsubstituted compounds (30a,b, 33a,b, 36a,b) at N-1 possessed higher potency than the substituted compounds (32a,b, 34a,b) for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds didnot have a significant activity. The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine.